KENNETH BATE - 20 Jun 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol
MDGL
Transactions as of
20 Jun 2025
Net transactions value
$0
Form type
4
Filing time
24 Jun 2025, 16:45:22 UTC
Previous filing
12 Jun 2025
Next filing
15 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BATE KENNETH Director C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Mardi Dier, as Attorney-in-Fact 24 Jun 2025 0001210238

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Award $0 +715 +37% $0.000000 2,627 20 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Award $0 +1,290 $0.000000 1,290 20 Jun 2025 Common Stock 1,290 $285.73 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date.
F2 The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date.